<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Atypical_Hemolytic_Uremic_Syndrome_Initial_Drug_Information_Q4</name>
        <optionSourceResponseValue>true</optionSourceResponseValue>
        <questionText>Instructions:
• For an initial application, complete section A
• For continuation at 6 months, complete Section B
• For annual renewal for ongoing treatment, complete Section C
All patients need to be reassessed yearly (or sooner) for continuation or discontinuation of eculizumab. 
Approval duration for eculizumab may be individualized based on the clinical circumstance.</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>Atypical_Hemolytic_Uremic_Syndrome_Initial_Drug_Information_Q4</developerName>
    <name>Atypical_Hemolytic_Uremic_Syndrome_Initial_Drug_Information_Q4</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
